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Sickle cell disease and β-thalassaemia are inherited haemoglobinopathies resulting in structural and
quantitative changes in the β-globin chain. These changes lead to instability of the generated hae-
moglobin or to globin chain imbalance, which in turn impact the oxidative environment both in-
tracellularly and extracellularly. The ensuing oxidative stress and the inability of the body to adequately
overcome it are, to a large extent, responsible for the pathophysiology of these diseases. This article
provides an overview of the main players and control mechanisms involved in the establishment of
oxidative stress in these haemoglobinopathies.
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Sickle cell disease (SCD) and β-thalassaemia are hereditary
autosomal recessive red cell disorders and major causes of mor-
bidity and mortality worldwide [200]. Their high prevalence is
attributed to the resistance they provide, in the heterozygous
state, to malaria infection [4]. It is estimated that 300,000–
500,000 infants are born annually with a β-globin disorder and
50,000–100,000 affected children die each year in low and middle
income countries [200].
In SCD a single amino acid substitution, from glutamic acid to
valine at position 6 of the β-globin protein results in the formation
of sickle haemoglobin (HbS), which has the propensity to poly-
merise under conditions of low oxygen saturation, such as in the
microcirculation. This in turn leads to the deformation ofFig. 1. (A) Intracellular oxidative events. (1) Oxidative denaturation of Hb. It results in the
Weiss reaction for the generation of hydroxyl radical. Haeme promotes oxidation reacti
superoxide by NADPH oxidase. NADPH oxidase is regulated by intra- (e.g. increased Ca2þ
(3) ROS and ROS-induced increase of intra-cellular Ca2þ activate caspase-3, which pa
increased Ca2þ also activate the KCC and Gardos channel respectively, resulting in incre
and phosphorylation of band-3 leading to band-3 clusterisation and dissociation from cyt
Band-3/haemachrome clusters are recognised by anti-band-3-NAbs. (5) ROS promote o
exposure results from ROS-induced disruption of normal membrane organisation. (B)
mopexin/haeme complexes are endocytosed by macrophages. Haeme is then degraded
Antioxidant enzymes and molecules in RBCs. (3) Stress-response mechanisms in RBCs.
expression of antioxidant genes. FOXO3 and HRI/eIF2α/ATF4 are important for termina
oxidative actions. AHSP binds α-globin in the absence of β-globin and in the presenc
selectively degraded via ubiquidin-mediated proteasomal degradation (UPS). When UPS
macroautophagy.erythrocytes containing the HbS polymers, which can block blood
vessels in the microcirculation impairing oxygen delivery to tis-
sues. A subsequent series of complications, such as pain crises,
pulmonary hypertension and heart failure, comprise the char-
acteristic symptoms of the disease [172].
β-thalassaemia is a highly heterogeneous group of genetic de-
fects leading to decreased or absent β-globin production. More
than 200 β-thalassaemia mutations have been currently identiﬁed
affecting transcriptional and post-transcriptional processes
(http://www.ithanet.eu) [1]. Insufﬁcient β-globin production re-
sults in the accumulation and precipitation of unpaired α-globin
chains, leading to haemolysis and ineffective erythropoiesis, which
give rise to severe anaemia and a series of secondary complica-
tions, such as skeletal abnormalities, splenomegaly and growth
defects [172].production of ROS, free haeme and iron. Iron acts as a Fenton reagent in the Haber–
ons and a proinﬂammatory effect by activating NF-κB. (2) Enzymatic generation of
) and extra-cellular (pro-inﬂammatory cytokines) signals that are activated by ROS.
rtially degrades band-3, affecting its interaction with the cytoskeleton. ROS and
ased exit of Kþ from the cell. (4) Haemichromes mediate the oxidative crosslinking
oskeletal proteins. This results in membrane blebbing and microparticle generation.
xidation of protein 4.1, actin and spectrin resulting in impaired interaction. (6) PS
Protective mechanisms in RBCs and the circulation. (1) Haptoglobin/Hb and hae-
by HO-1 releasing biliverdin, CO and iron. Iron is then taken up by ferritin. (2)
FOXO3, HRI/eIF2α/ATF4 and NRF2 are oxidant-response pathways that regulate the
l differentiation. PRDX2 is a chaperone of Hb and binds free haeme to prevent its
e of oxidant insults. (4) Protein quality control pathways. Unpaired α-globins are
becomes overwhelmed, α-globin aggregates are degraded via aggresome-mediated
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2.1. Oxidative denaturation of haemoglobin
Although oxygenated haemoglobin [Hb(FeII)O2] is considered a
relatively stable molecule, it can physiologically autoxidize to
methaemoglobin [Hb(FeIII)] (Eq. (1)) at a rate 0.5–3% per day
(Fig. 1A) [193]. Autoxidation is most pronounced under hypoxic
conditions (e.g. in the microcirculation) and for unstable hae-
moglobins (Hb) such as HbS or free α-globin chains [169]. Auto-
xidation is almost entirely responsible for reactive oxygen species
(ROS) generation inside red blood cells (RBCs) [195]. In SCD and β-
thalassaemia RBCs, Hb autoxidation is more pronounced as the
Hbs molecules in these diseases are highly unstable [169].
HbFe II O HbFe III O 12 22( ) → ( ) + ( )−
The superoxide ions ( O2
•−) produced by Hb autoxidation are
rapidly converted to hydrogen peroxide (H2O2) either by sponta-
neous or enzyme-driven (superoxide dismutase) dismutation (Eq.
(2)) [169,81].
2O 2H H O O 22 2 2 2+ → + ( )•− +
H2O2 can react with both oxyHb Eq. (3) and metHb (Eq. (4))
producing ferryHb [HbFe(IV)¼O] (and oxyferryHb [HbFe(IV)¼O]
respectively [169,81].
HbFe II O H O HbFe IV O H O O 32 2 2 2 2( ) + → ( ) = + + ( )
HbFe III H O HbFe IV O H O 42 2 2( ) + → ( ) = + ( )•
FerryHb and oxyferryHb can subsequently react with H2O2
producing metHb (Eqs. (5) and (6)) [169,81].
HbFe IV O H O HbFe III O H O 52 2 2 2( ) = + → ( ) + + ( )•−
HbFe IV O H O HbFe III O H O 62 2 2 2( ) = + → ( ) + + ( )•
It has been noted that haeme has a lower afﬁnity to metHb
than oxyHb, and this results in increased dissociation of haeme
[35]. In vitro studies have shown that H2O2 can react with free
haeme with subsequent haeme degradation and iron release [130].
In addition, the reaction of ferryHb with H2O2 (Eq. (5)) results in
the production of O2
•− within the haeme pocket, which promotes
haeme degradation and the subsequent release of haeme de-
gradation products and iron [Fe(III)] [130].
2.2. Haeme and iron as oxidising molecules
Haeme and iron are highly oxidising agents. In fact iron, either
in free form or bound to haeme and Hb, can act as a Fenton re-
agent in the Haber–Weiss cycle, which generates the highly re-
active hydroxyl radical (OH) (Eq. (7)) (Fig. 1A) [171]. Unlike O2•−,
hydroxyl radicals cannot be eliminated enzymatically and can,
therefore, promote extensive oxidative damage [166]. Iron chela-
tors have been shown to reduce lipid peroxidation in RBC mem-
branes suggesting that ROS generation and oxidant damage are
partially dependant on iron [178]. Reducing iron availability has
also been shown to lessen the deposition of α-globin aggregates
which leads to reduction of ineffective erythropoiesis in β-tha-
lassaemia [105].
H O Fe II OH OH Fe III 72 2 + ( ) → + + ( ) ( )• −
Haeme is a hydrophobic molecule that can interact with
membrane lipids and proteins promoting oxidation reactions
(Fig. 1A) [22]. Haeme has the ability to activate the redox sensitive
transcription factor nuclear factor-κB (NF-κB) and promotes aproinﬂammatory effect by binding to receptors, enzymes and
transcription factors and alters cell function, metabolism and gene
expression (Fig. 1A) [199]. Moreover, haeme can oxidatively de-
nature DNA, activate caspases and cathepsins, impair mitochon-
drial function and affect the activity of antioxidant enzymes, such
as glutathione reductase [132,169,191].
2.3. Enzymatic generation of ROS in SCD RBCs
Interestingly, a recent study by George et al. [63] has shown
that in SCD RBC apart from Hb autoxidation and the Fenton re-
action, ROS can also be generated enzymatically by NADPH oxi-
dase (Fig. 1A). NADPH oxidase activity seems to be regulated by
PKC, Rac GTPase and Ca2þ signalling inside RBCs, and is increased
by TGFβ1 and endothelin1 cytokines, which show increased ac-
tivity in SCD [63].3. Intracellular oxidative events
3.1. Phospholipid asymmetry, phosphatidylserine exposure and
eryptosis
Partial oxygenation of Hb in the microcirculation results in Hb
conformational changes that are not only responsible for increased
autoxidation [19] but also for increased afﬁnity to the plasma
membrane [37]. Therefore, partially oxygenated Hb, especially if it
is unstable, is responsible for the majority of ROS generated at the
RBC membrane [125]. However, ROS located at the plasma mem-
brane are not readily accessible to the cytoplasmic antioxidant
system [125] and can easily oxidise membrane lipids and proteins,
causing extensive oxidative damage [24]. This can be further ex-
acerbated in SCD and in β-thalasssemia RBC where increased and
continuous production of ROS as a result of enhanced Hb auto-
xidation rapidly overwhelms the limited membrane antioxidants
(e.g. such as vitamins E and C, glutathione peroxidase and perox-
iredoxin-2) available [122,128,129,42].
Lipid peroxidation and protein oxidation result in loss of
membrane lipid organisation and cellular deformability [24,95].
Cellular deformability is very important for RBC function as these
have to deform and squeeze through the capillaries in the mi-
crocirculation to efﬁciently transport oxygen to tissues [158]. Ad-
ditionally, the resulting disruption of the physiological asymmetry
of phospholipids causes phosphatidylserine (PS) exposure to the
outer membrane (Fig. 1A) [76]. PS is a signal for cell removal re-
cognised by scavenging receptors in macrophages, which engulf
and degrade the PS-exposed RBCs [88]. PS-exposed RBCs have
been observed in both SCD and β-thalassaemia [46,76]. Another
factor that leads to abnormal PS exposure in SCD is the repeated
cycles of sickling and unsickling, which disturb the membrane
phospholipid asymmetry and result in microvesicle formation [8].
PS exposure and subsequent macrophage degradation is the
mechanism of RBC removal during eryptosis. Eryptosis is the sui-
cidal RBC death, which occurs prior to senescence and after injury
of RBCs. It is characterised by cell shrinkage and loss of membrane
organisation and can be stimulated by oxidative stress, energy
depletion, increased Ca2þ concentration, caspases and disrupted
activity of several kinases like PKC and p38 MAPK [96], factors that
are observed in SCD and β-thalassaemia.
3.2. Haemichrome formation, band-3 oxidation and senescence
Modiﬁcations in structure and function of membrane compo-
nents are also caused by the direct precipitation of denatured
haemoglobins or globin chains. SCD and β-thalassaemia are char-
acterized by unstable haemoglobin molecules. In β-thalassaemia
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chains resulting in excess free α-globins, whereas in SCD the
mutation that affects the tertiary and quaternary structure of HbS
renders it easily denatured. Unstable haemoglobins tend to auto-
xidize, denature and precipitate as haemichromes [149]. Haemi-
chromes are structures that consist of all the intermediate pro-
ducts of haemoglobin oxidative denaturation, starting from metHb
until complete dissociation and release of haeme and iron [160].
Haemichromes have a high afﬁnity for the cytoplasmic domain
of band-3 and mediate the oxidative crosslinking through dis-
ulphide bonds (Fig. 1A) [116]. Upon band-3 oxidation tyrosine ki-
nases, activated by oxidative stress, phosphorylate the cytoplasmic
domain of band-3 [149,32]. This results in band-3 clusterization
and dissociation from cytoskeletal proteins through disruption of
ankyrin binding [116,59]. The resultant membrane blebbing and
microparticle generation are important characteristics of SCD and
β-thalassaemia [201].
A function of band-3 is to bind glycolytic enzymes and organise
them on the membrane thus regulating the ﬂux of glucose be-
tween glycolysis and the PPP. Therefore, the dislodgement of gly-
colytic enzymes from oxidised band-3 results in the activation of
glycolysis and reduced NADPH production from the PPP [71].
NADPH is an important reducing agent of GSH and peroxiredoxin
thus offering protection against oxidative stress [30]. Conse-
quently, reduction in the levels of NADPH decreases the anti-
oxidant capacity of RBCs and further exacerbates oxidative stress.
Moreover, naturally occurring anti-band-3 antibodies (NAbs)
have a high afﬁnity for the band-3/haemichrome clusters. Upon
binding to the clusters they activate complement and trigger RBC
clearance by macrophages (Fig. 1A) [111,116]. Anti-band-3 NAbs
binding and complement activation are implicated in the removal
of senescent RBCs and are also seen in haemolytic disorders such
as SCD and β-thalassaemia [116,82].
3.3. Oxidative stress and the cytoskeleton
Oxidative stress has an effect not only on membrane but also
on cytoskeletal proteins. Shinar et al. [180] demonstrated that in β-
thalassaemia patients protein 4.1 exhibits a signiﬁcant reduction
both in its ability to increase the binding of spectrin to actin but
also in its own ability to bind to spectrin. Spectrin is a major target
of ROS and its oxidation results in disruption of its interaction with
other cytoskeletal proteins like actin or with proteins that bridge
the membrane and the cytoskeleton such as protein 4.1 (Fig. 1A)
[180]. This leads to impaired stability in the interaction between
membrane and cytoskeleton and thus increased fragility. In addi-
tion, when β-thalassaemia RBC membranes were resolved by gel
chromatography, a-globin chains were co-puriﬁed with cytoske-
letal proteins such as spectrin, actin and protein 4.1 [179]. Fur-
thermore, α-globin aggregates were shown to colocalize with re-
gions of defective association of spectrin and protein 4.1 in β-
thalassaemia erythroblasts (Fig. 1A) [7]. This may result in inter-
ruption of the normal assembly of the cytoskeletal proteins and
also in their oxidation as α-globin aggregates tend to easily
autoxidise.
Oxidation of spectrin, actin and protein 4.1 has been observed
in SCD RBCs [175,67]. Additionally, George et al. [64] have de-
monstrated increased phosphorylation of adducin at Ser-726, a
target of PKC, in SCD RBCs [64]. The phosphorylation of adducin is
known to result in dissociation of spectrin from F-actin. PKC,
whose activity is increased in SCD regulates the activity of NADPH
oxidase in SCD RBCs resulting in increased ROS production [63].
3.4. ROS as signalling molecules and their involvement in haemolysis
ROS not only function as oxidising molecules but are also ableto modulate the activity of transcription factors, membrane
channels, and metabolic enzymes and thus integrate into signal-
ling pathways [104], possibly through oxidation of protein thiols
[143]. Caspase-3 activation has been linked to increased ROS
production in RBCs [119,43]. Caspase-3 is normally produced
during erythropoiesis and cleaves GATA-1, Tal-1 and proteins in-
volved in cytoskeletal and DNA integrity, initiating a cell death
programme when erythropoietin (EPO) levels are low [212,51].
ROS-activated caspase-3 leads to partial degradation of band-3,
affecting its interaction with cytosolic proteins and the cytoske-
leton (Fig. 1A) [113]. The resulting impairment of membrane
structure can lead to PS exposure [114]. In addition, oxidative
stress has been shown to result in inhibition of the Ca2þ-ATPase
pump in red blood cells [88] and the activation of Ca2þ-permeable
unselective cation channels with subsequent increase in in-
tracellular Ca2þ (Fig. 1A) [60]. This leads to activation of calpain,
transglutaminase-2 and caspases, which can degrade cytoskeletal
proteins and decrease cell stability [164]. Moreover, increased in-
tracellular Ca2þ has been shown to inhibit phosphotyrosine
phosphatase thus increasing band-3 phosphorylation [215], and
also to reduce ﬂippase activity leading to membrane scrambling
and PS exposure [36]. Elevated Ca2þ has also been shown to result
in activation of the Gardos channel with subsequent exit of Kþ
(Fig. 1A). These changes in cation homoeostasis lead to water re-
moval and therefore cell shrinkage [137,204,23], which is a char-
acteristic of eryptosis [96]. Oxidative stress has also been found to
affect the activity of the K–Cl co-transporter (KCC) in β-tha-
lassaemia RBCs (Fig. 1A). The increased KCC activity results in
enhanced exit of Kþ from RBCs [142,50]. However increased exit of
Kþ can dissipate the Kþ gradient across the membrane and lead to
membrane depolarisation. This results in entry of Cl with os-
motically obliged water and subsequent cell swelling, cell mem-
brane disruption and haemolysis [97].
As previously mentioned, in SCD and β-thalassaemia signs of
increased senescence and eryptosis can be observed. However, in
cases of extensive oxidative injury RBCs will become damaged to
such an extent that they will not be removed by a controlled
mechanism such as senescence or eryptosis but will be haemo-
lysed [195]. Increased haemolysis has been seen in both SCD and
β-thalassaemia [176,39].
3.5. Oxidative stress and ineffective erythropoiesis
Ineffective erythropoiesis is well documented in β-thalassaemia
and is attributed to the presence of excess unpaired α-globins
[168]. Unpaired α-globins have the tendency to precipitate and
autoxidise producing high amounts of ROS, free haeme and iron
[169]. As previously mentioned, these molecules can promote
oxidation of membrane lipids and proteins resulting in band-3
clusterisation and PS exposure [116,76]. These are signs of senes-
cence and eryptosis of RBCs, which are then removed by macro-
phages. Several studies have shown that there is an increased
number of activated macrophages in the bone marrow of β-tha-
lassaemia patients,indicative of enhanced senescence and er-
yptosis of erythroid precursors (Fig. 2) [11,38]. Interestingly,
Wickramasinghe and Bush [203] have demonstrated the presence
of α-globin precipitates in cells at the polychromatophilic ery-
throblast stage of mauration [203], which is the stage of increased
haemoglobinization and apoptosis in β-thalassaemia erythropoi-
esis (Fig. 2) [120].
Recently, Dussiot et al. [53] have shown that growth differ-
entiation factor 11 (GDF11), a TGFβ superfamily ligand, blocks
terminal differentiation of erythroid precursors in a mouse model
of β-thalassaemia intermedia by promoting oxidative stress and α-
globin precipitation. In addition, GDF11 induces apoptosis of early
erythroblasts by inhibiting the Fas–Fas ligand pathway. More
Fig. 2. Oxidative events in the bone marrow and circulation. (1) Erythroid expansion. (2) Ineffective erythropoiesis. (3) Endocytosis of RBCs by macrophages through two
different mechanisms: eryptosis and senescence. (4) Haemolysis. It leads to Hb release in the plasma, which subsequently autoxidises producing ROS, free haeme and iron.
(5) ROS, free haeme and iron intercalate into plasma membranes producing oxidative damage to the endothelium and haematopoietic cells. ROS and haeme activate NF-κB
and AP-1, which increase the production of pro-inﬂammatory cytokines (IL-1, IL-6, TNFα) and adhesion molecules on the endothelium. This increases the adhesion of RBCs,
leucocytes and platelets to the endothelium. Activated leucocytes generate more ROS by their NADPH oxidase, creating a vicious cycle of oxidative stress and inﬂammation.
(6) Reduction of NO bioavailability due to free Hb, ROS, and neutrophil activation, (7) Increased expression of plasma and endothelial enzymes (e.g. xanthine oxidase, NADPH
oxidase and iNOS) following I/R gives rise to more ROS.
S. Voskou et al. / Redox Biology 6 (2015) 226–239230importantly, GDF11 expression is induced by oxidative stress, in-
dicating the presence of an autocrine ampliﬁcation loop that
promotes ineffective erythropoiesis [53].
Ineffective erythropoiesis has also been observed in human and
mouse SCD [208,31]. Blouin et al. [31] have demonstrated that the
late precursors (polychromatophilic normoblasts to reticulocytes)
of a transgenic SCD mouse model presented altered morphology
and increased fragmentation, which were attributed to the in-
creased HbS polymerisation [31]. Interestingly, they suggested that
the latter happens during medullary migration of reticulocytes to
the periphery. Although there is little published information re-
garding the effects of oxidative stress on SCD ineffective ery-
thropoiesis, the afore-mentioned study has attributed the ob-
served ineffective erythropoiesis to the increased HbS poly-
merisation, which is known to be associated with enhanced au-
toxidation and ROS generation [169].
3.6. ROS implication in erythroid expansion and accelerated
differentiation
In β-thalassaemia, ineffective erythropoiesis and haemolysis
give rise to chronic anaemia, which results in tissue hypoxia and
subsequent increase in EPO production. This in turn leads to en-
hanced extramedullary and bone marrow erythropoiesis, which is
characterised by increase erythroid proliferation and accelerated
differentiation (Fig. 2) [120,38]. A recent study has implicated
ROS in the increased proliferation and differentiation of
β-thalassaemia/HbE erythroid precursors [103]. Leecharoenkiat et
al. [103] suggested a model where an increase in aerobic respira-
tion would result in increased levels of ATP. This could lead to an
increase in Ca2þ intracellular levels possibly through activation of
Ca2þ pumps. High Ca2þ levels stimulate oxidative phosphoryla-
tion resulting in further increase of ATP. ATP can directly or in-
directly, through cAMP or Ca2þ , activate several ERK1/2 effectors
such as PKA, PKB, and PKC. ROS, which are by-products of aerobic
metabolism, are also able to activate these effectors, which in turn
can increase proliferation and differentiation both directly or in-
directly via ERK1/2 phosphorylation. Increased erythroid pro-
liferation and differentiation lead to increased metabolic ratescreating a feedback loop. Therefore even a small initial imbalance
in ROS could rapidly result in a signiﬁcant negative outcome. This
imbalance could be due to increased autoxidation of unstable Hbs
or due to increased iron levels, both known to occur in β-tha-
lassaemia [103].
Increased erythroid expansion has also been observed in SCD
with spleen, rather than of bone marrow, being the predominant
erythropoietic organ [85]. In fact, Kean et al. [85] have demon-
strated that there is much higher erythroid hyperplasia in SCD
mice compared to β-thalassaemic animals, having almost 3 fold
more RBCs in their erythropoietic organs, mainly in the spleen. In
addition, Blouin et al. [31] have observed in a transgenic SCD
mouse model increased mobilisation of erythroid progenitors from
the bone marrow to the periphery and subsequently to the spleen
for immediate maturation [31]. Although, there are no publica-
tions on the effects of oxidative stress on the increased erythroid
proliferation in SCD, the above model can also be supported by
SCD, as enhanced autoxidation of HbS can promote excessive ROS
production [169].4. Protective mechanisms in rbcs
4.1. Antioxidant enzymes and molecules
Energy production in RBCs is dependant on the anaerobic de-
gradation of glucose through the glycolytic pathway and sub-
sequent lactate production as RBCs are devoid of mitochondria
[30]. NADH produced by glycolysis is the main reducing agent of
metHb, maintaining Hb in the ferrous state. The reaction is cata-
lysed by the NADH-dependant cytochrome b5 reductase enzyme
[153]. The increased production of metHb in SCD and β-tha-
lassaemia may thus result in enhanced glycolysis due to increased
NADH demand [140].
Glucose-6-phosphate is used not only during glycolysis but also
in the pentose phosphate pathway (PPP) for the reduction of
NADPþ to NADPH (Fig. 1B) [30]. NADPH is the reducing agent used
by glutathione reductase for the reduction of oxidised glutathione
(GSSG) to two molecules of glutathione (GSH). GSH is an
S. Voskou et al. / Redox Biology 6 (2015) 226–239 231important antioxidant molecule of the glutathione cycle and it is
used by several enzymes as a reducing agent (Fig. 1B). Glutathione
peroxidase and peroxiredoxin generate GSSG during the reduction
of peroxides (e.g. H2O2) and organic hydroperoxides (ROOH),
whereas glutaredoxin uses GSH as a cofactor to reduce oxidised
proteins and ascorbate. Additionally, glutathione-S-transferase
utilises GSH to detoxify xenobiotics [115,195].
Thioredoxin is another antioxidant enzyme in RBCs, which re-
duces oxidised proteins and acts as electron donor to peroxir-
edoxin (Fig. 1B). It is kept in its reduced form by thioredoxin re-
ductase, which uses NADPH as the reducing agent [12,195]. Su-
peroxide dismutase is the enzyme that converts O2
•− to H2O2, and
subsequently catalase neutralises H2O2 to water and oxygen
(Fig. 1B) [195]. Finally, RBCs can take up large amounts of vitamin C
and vitamin E as they are used to protect against membrane oxi-
dative damage [122,42].
In SCD and β–thalassaemia, the antioxidant enzymes and mo-
lecules are signiﬁcantly decreased, although no defects in their
expression and metabolism have been demonstrated. Instead, the
increased and continuous production of ROS overwhelms the an-
tioxidant machinery very rapidly [167].
4.2. Cytoprotective mechanisms during normal erythropoiesis and
oxidative stress conditions
An interesting study by De Franceschi et al. [48] has proposed
the presence of two stress-response cytoprotective mechanisms in
β-thalassaemia erythropoiesis. ROS and haeme have been shown
to reduce the activity of δ-aminolevulinate synthase-2, which is
the rate limiting enzyme in the haeme production pathway. In
addition, ROS seem to increase the expression of peroxiredoxin-2
(PRDX2) (Fig. 1B), which has a multifactorial role inside RBCs [48].
PRDX2 is mainly an antioxidant enzyme and reduces peroxides
and thiols [141]. PRDX2 can translocate to the membrane through
binding to the cytoplasmic domain of band-3 [121,154], probably
to protect band-3 and its associated proteins from oxidative da-
mage [49]. Haemichromes seem to prevent this translocation by
masking the docking site for PRDX2 [49]. PRDX2 has also been
shown to function as a molecular chaperone of Hb, both during
erythropoiesis by maintaining proper Hb folding and after ma-
turation by preventing Hb denaturation [109,184]. Moreover, it
binds free haeme with high afﬁnity possibly to prevent haeme’s
oxidative actions [48].
Alpha-stabilizing protein (AHSP) is another molecular chaper-
one that is present in RBCs (Fig. 1B). It binds free α-globin chains,
maintaining their native structure en route to HbA synthesis [211].
More importantly, in the absence of β-globin and in the presence
of oxidant insults it promotes structural changes to HbA so that
the iron will not be able to catalyse redox reactions [214,56]. De-
creased levels of AHSP exacerbate the phenotype of β-thalassae-
mia [91].
The haeme regulated inhibitor of protein translation (HRI)
provides another cytoprotective mechanism (Fig. 1B). HRI re-
presses globin translation, by phosphorylating the eukaryotic
translation initiation factor 2α (eIF2α), during haeme deﬁciency
[40], however, oxidative stress leads to activation of HRI in-
dependently of haeme levels [110]. Phosphorylated eIF2α inhibits
general protein translation to avoid proteotoxicity and simulta-
neously increases the translation of selective mRNAs like ATF4 in
order to initiate a stress response cascade [70]. Interestingly, the
HRI/eIF2α/ATF4 signalling appears to be activated during ery-
thropoiesis, possibly to reduce oxidative stress at the haemoglo-
binization stage. In fact, Hri knockdown foetal liver cells develop
ineffective erythropoiesis during ex vivo differentiation [186], and
the phenotypic severity of β-thalassaemia mice is exacerbated
when Hri is deﬁcient [69].It appears that modulation of oxidative stress is signiﬁcant
during erythropoiesis since the production of Hb requires the
uptake of haeme and iron, which are extremely oxidising mole-
cules [65]. The importance of ROS modulation during erythroid
maturation can be seen in G6pdΔES mouse cells where deﬁnitive
erythrocytes apoptose at the stage of increased haemoglobiniza-
tion. Importantly, their death is hindered by reducing agents [147].
Glucose 6-phosphate dehydrogenase (G6PD) is an enzyme of the
PPP that produces NADPH, which is an important reducing agent
[30]. This study indicates that in order to reach terminal differ-
entiation and avoid apoptosis erythroid cells have to overcome
oxidative stress.
HRI/eIF2α/ATF appears to be one of the pathways that combat
ROS production during erythroid differentiation [186]. In addition,
NRF2 and FOXO3α are two other well-known antioxidant protec-
tive signalling factors/pathways [117,84] (Fig. 1B). NRF2, an anti-
oxidant transcription factor, induces the expression of haeme
oxygenase-1 (HO-1), which is the rate limiting enzyme of haeme
degradation [90]. Haeme appears to increase the stability of the
NRF2 protein [5]. Interestingly, HRI/ATF4 is also implicated in HO-1
expression during ex vivo erythropoiesis or oxidative stress con-
ditions [186]. Therefore, HRI seems not only to regulate globin
synthesis according to haeme availability, but also alleviates ex-
cess, toxic levels of haeme by inducing HO-1 expression [186].
Additionally, NRF2 and ATF4 have been found to interact in order
to promote HO-1 expression [72]. Moreover, NRF2 and HRI/ATF4
appear to have several other similar targets such as NQO1 (NADPH
quinone oxidoreductase 1) and GST (glutathione-S-transferase),
whose expression is increased in order to promote stress response
signalling [146,70].
FOXO3α has been found to be activated at an intermediate stage
of erythroid differentiation and remains active until terminal
maturation. The signal for FOXO3α nuclear localisation and acti-
vation is provided by the downregulation of EPO/PI3K/AKT sig-
nalling at the stage of increased haemoglobinization in order to
prevent ROS accumulation [117]. FOXO3α expression is also in-
duced by oxidative stress and in response to that FOXO3α pro-
motes cell cycle arrest in order to repair DNA damage or induces
apoptosis [118,192,52,66]. FOXO3α upregulates the expression of
several antioxidant enzymes such as SOD and catalase [136,93],
and inhibits the proliferation of intermediate erythroid precursors
in order to allow the erythroid differentiation programme to occur
[117]. In fact FOXO3α seems to synchronise erythroid proliferation
and maturation throughan oxidative stress-mediated process.
Mice deﬁcient in FOXO3α die due to oxidative stress-induced in-
effective erythropoiesis and this is possibly attributed to a hin-
dered FOXO3α haematopoietic response [117].
4.3. Protein quality control pathways in β-thalassaemia
A novel yet little-studied ﬁeld involves the role of protein
quality control (PQC) pathways during erythropoiesis and their
deregulation during β-thalassaemia. Khandros and Weiss [87]
suggested that β-thalassaemia is a protein aggregation disorder
that uses PQC pathways as defence mechanisms. During ery-
thropoiesis the cell balances the production of individual globins,
which are unstable and toxic in the absence of their partners. This
supports the notion that the cell senses and regulates a possible
imbalance. Additionally, β-thalassaemia trait individuals are rela-
tively unaffected, which indicates that there is a threshold above
which excess α-globin is detrimental [87].
Recent studies have shown that early erythroid precursors can
balance globin levels through selective α-globin ubiquitin-medi-
ated proteasomal (UPS) degradation (Fig. 1B) [177,196]. UPS has a
physiological function during normal erythropoiesis, which is not
only to degrade α-globin but also unnecessary proteins before the
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lassaemia, α-globin proteolysis was increased compared to healthy
individuals or patients with other anaemias [196,33].
However, during late stages of erythropoiesis, either normal or
thalassaemic, α-globins tend to accumulate and proteasomal ca-
pacity rapidly becomes overwhelmed [177,196]. Interestingly,
Khandros et al. [86] have shown that although short-term pro-
teasomal inhibition in β-thalassaemia cells prevented α-globin
degradation, prolonged proteasomal inhibition in β-thalassaemia
mice did not enhance α-globin accumulation but rather stimulated
compensatory PQC pathways such as autophagy and heat shock
chaperones. This indicates that multiple PQC pathways are co-
ordinately activated in β-thalassaemia and that there is molecular
cross-talk between them [86].
Autophagy is another physiological process that takes place
during erythropoiesis. Reticulocytes degrade mitochondria and
other organelles using macroautophagy [213], which is upregu-
lated by GATA-1 [80]. Interestingly, electron micrographs of β-
thalassaemia precursors have detected α-globin aggregates within
lysosomes [203]. Additionally, autophagy appears to be upregu-
lated in β-thalassaemia/HbE erythroblasts [108]. Khandros et al.
[86] suggested that while moderate amounts of α-globin can be
degraded by UPS, higher amounts tend to precipitate and are de-
graded via aggresome-mediated macroautophagy (Fig. 1B) [86].
Aggresomes are dynamic structures where insoluble proteins in-
teract with the PQC machinery and provide a staging area where
abnormal proteins can be sequestered for refolding, UPS de-
gradation or autophagy [92].
Although the above studies have been performed in a β-tha-
lassaemia setting, Basu et al. [25], using a 2D DIGE based pro-
teomic approach, have demonstrated upregulation of proteasomal
subunits and chaperones, such as AHSP and HSP70 in the cytosol
of SCD RBCs compared to healthy RBCs [25].5. Extracellular oxidative events
Upon haemolysis, Hb is released in the plasma and oxidative
reactions take place that result in ROS generation, haeme and iron
release (Fig. 2) [169,81]. These toxic molecules can intercalate into
cell membranes and promote oxidative damage to the en-
dothelium, haematopoietic cells and various organs (Fig. 2)
[22,57]. In SCD and β-thalassaemia, signs of oxidative stress can be
observed not just in RBCs but also in leucocytes, platelets, en-
dothelial cells and several other tissues [10,29].
As previously mentioned, haeme and iron are considerably
toxic molecules. Plasma free iron has been linked to carbonyl
group production in plasma proteins, which is an indication of
increased protein oxidation [44]. In addition, haeme can bind
plasma proteins such as albumin and LDL [124,173]. Upon binding
to LDL, haeme iron promotes its oxidation, which has a major ef-
fect on the generation of atherosclerotic plaques. Atherosclerotic
plaques can promote lysis of RBCs and oxidation ofHb molecules.
Free haeme and iron released by these oxidation reactions can
further oxidise plaque components resulting in additional damage
of the endothelium [131].
5.1. Protective mechanisms in the circulation
Several protective mechanisms function in order to avoid the
detrimental effects of ROS, free haeme and iron. However, in cases
of increased haemolysis these protective mechanisms become
overwhelmed. Haptoglobin and haemopexin, whose levels are
reduced in SCD and β-thalassaemia, scavenge Hb and haeme re-
spectively (Fig. 1B). Haptoglobin-Hb complexes bind to CD163 re-
ceptors on macrophages, whereas the haemopexin–haemecomplexes are recognised by receptors on hepatic parenchymal
cells and macrophages. Following binding to receptors the com-
plexes are endocytosed [182,34]. Upon entering the cell haeme
drives expression of HO-1, biliverdin reductase and ferritin. Haeme
is broken down to biliverdin, releasing carbon monoxide and iron
(Fig. 1B) [41]. The latter can be taken up by ferritin in order to
prevent oxidative reactions. Patients with SCD have increased
cellular HO-1 protein levels in their polymorphonuclear cells
(PMNs) compared to healthy volunteers [78]. Increased HO-1 ex-
pression was also observed in renal tubular epithelial cells and
circulating endothelial cells of patients with SCD [133].
5.2. A vicious cycle of oxidative stress and inﬂammation
A major effect of haeme and ROS released into the circulation is
to promote vascular inﬂammation by activating NF-κB and AP-1,
which can then increase the expression of pro-inﬂammatory cy-
tokines (IL1, IL6, TNFα) and adhesion molecules (L-selectin, P-se-
lectin, VCAM-1, ICAM-1) on the endothelium (Fig. 2) [199]. This
leads to increased adhesion of RBCs, leucocytes and platelets to the
endothelium resulting in endothelial activation and dysfunction
[62]. In addition, the produced pro-inﬂammatory cytokines pro-
mote the generation of additional ROS [63], while increased re-
cruitment and adhesion of leucocytes to the endothelium can add
to that effect [199]. Increased leucocyte inﬂux is not only an im-
portant inﬂammatory marker but also a major source of ROS due
to the superoxide producing enzyme NADPH oxidase (Fig. 2)
[209,99]. The chronic oxidative stress in SCD and β-thalassaemia
PMNs results in a reduced respiratory burst response, which is a
mechanism of destroying engulfed bacteria, and thus leads to re-
current infections [9].
NADPH oxidase is not only responsible for ROS production in
leucocytes but also in RBCs. As mentioned earlier, George et al.
[63] have demonstrated that ROS production in SCD RBCs is not
only generated by Hb autoxidation and Fenton reaction but also
enzymatically by NADPH oxidase. Inside RBCs, NADPH oxidase
activity seems to be regulated by PKC, Rac GTPase and Ca2þ sig-
nalling and is increased by TGFβ1 and endothelin1 cytokines,
which have been shown to be enhanced in SCD (Fig. 1A) [63].
Therefore, it appears that NADPH oxidase-mediated ROS and sys-
temic inﬂammation function within a vicious cycle since ROS are
responsible for increased pro-inﬂammatory cytokine expression
[199], and TGFβ1 and endothelin1 cytokines appear to increase
ROS production by modulating NADPH oxidase activity [63].
5.3. Hypercoagulation in SCD and β-thalassaemia
SCD and β-thalassaemia are characterized by increased hy-
percoagulability as demonstrated by the increased markers of
platelet activation and thrombin production [202,205,94]. Chronic
oxidative damage of platelets [10] and adhesion to the en-
dothelium can lead to their activation and aggregation (Fig. 2)
[101,77]. Additionally, PS-exposed RBCs can adhere to the en-
dothelium and activate the coagulation process. They provide a
docking site for coagulation factor X and prothrombinase com-
plexes, which can then be converted to activated factor X and
thrombin respectively [216]. Another factor that adds to the hy-
percoagulation state observed in SCD and β-thalassaemia is the
presence of tissue factor (TF) in endothelial cells. ROS can directly
damage the endothelium by mediating oxidation reactions with
membrane lipids and proteins [29,68]. This results in endothelial
cell swelling and disengagement from the basement membrane,
which eventually leads to TF exposure on the endothelial cell
membrane [183]. Coagulation factor VII, the primary initiator of
coagulation process, can bind to TF [134].
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properties
Reduction of nitric oxide (NO) bioavailability plays an im-
portant role in endothelial dysfunction, thrombosis and in-
ﬂammation [14]. NO is a freely diffusible intercellular messenger,
produced by a variety of mammalian cells including vascular en-
dothelium, neurons, smooth muscle cells, macrophages, neu-
trophils, platelets and pulmonary epithelium [123]. Once formed,
NO diffuses to nearby smooth muscle cells in which it reacts with
the ferrous iron of the haeme group of guanylate cyclase, resulting
in enhanced synthesis of cyclic guanosine monophosphate (cGMP)
from guanosine triphosphate (GTP) [126]. Cyclic GMP then acti-
vates protein kinase G (PKG) which stimulates the
Ca2þ-ATPase-dependant reﬁlling of intracellular calcium stores
and lowers intracellular calcium levels, thus mediating smooth
muscle cell relaxation [106]. In addition, NO promotes vasodilation
by up-regulating the endothelial vasodilator endothelin receptor B
and down-regulating the vasoconstrictor endothelin-1 [185]. The
cGMP/PKG-dependant signalling mechanism also promotes a po-
tent inhibition of platelet aggregation [161]. NO's anti-thombotic
properties also include inhibition of platelet activation and adhe-
sion to the endothelium, TF expression and thrombin formation
[58]. NO is also an important antagonist of inﬂammation [47]. It
inhibits NF-κB activation through induction of the NF-κB inhibitor,
IκBα expression and stabilisation of the NF-κΒb/IκBα complex
[152]. NF-κB regulates the expression of genes involved in in-
ﬂammatory and immune responses such as VCAM-1, ICAM-1,
P-selectin and E-selectin [2].
5.5. Reduced NO bioavailability
NO's vasodilating, anti-thrombotic, and anti-inﬂammatory
properties are reduced in SCD and β-thalassaemia as a result of
decreased NO bioavailability (Fig. 3) owing to increased haemo-
lysis [165] and ROS generation (Fig. 2) [18]. NO binds very rapidly
to free deoxyHb in the plasma and forms a stable Hb (Fe2þ)-NOFig. 3. Scheme of intravascular nitric oxide consumption in sickle cell disease. Superoxid
with NO to form peroxynitrite (ONOO). Nitric oxide is also consumed by plasma free h
reaction between MPO and hydrogen peroxide (H2O2) results in the formation of comp
oxidise halides in a single two-electron step or can oxidise multiple substrates through
(Asc) are abundant substrates that can undergo one-electron oxidation by MPO-compou
with both tyrosyl and ascorbyl radicals is diffusion limited and leads to the catalytic cocomplex [74]. NO also reacts with oxyHb and leads to the forma-
tion of metHb and NO3– [74]. Additionally, superoxide binds to NO
to produce peroxinitrite (ONOO) and thus not only contributes in
the reduction of NO levels but also leads to further ROS generation
[16,28]. The release of arginase during haemolysis is another factor
that contributes to low NO levels. Arginase competes with nitric
oxide synthase (NOS) for its substrate, L-arginine, which it uses to
produce NO and L-citrulline [207]. NOS requires the cofactor tet-
rahydrobiopterin (BH4) to provide an electron for the reaction that
hydroxylates L-arginine to N-hydroxy-L-arginine (NHA) [27]. Once
NHA is formed, it is reduced to yield the ﬁnal products NO and L-
citrulline [6]. The absence of BH4, due to peroxinitrite production,
or L-arginine leads to the decay of Fe2þ-dioxygen (Fe2þ¼O2)
complex by forming O2
•− and Fe3þ , an observable fact that is
known as ‘uncoupling’ of NOS and results in further ROS produc-
tion [157]. Another factor that leads to NOS uncoupling is asym-
metric dimethyl-arginine (ADMA). ADMA is a NO synthase in-
hibitor, which competes with L-arginine for NOS [210,61] and its
levels were shown to be increased in SCD patients [174].
Depletion of GSH in SCD neutrophils and signiﬁcantly increased
cyclooxygenase (COX) activity may also impact on rates of NO
consumption and reﬂects increased oxidative stress associated
with neutrophil activation [13]. Haeme-containing myeloperox-
idase (MPO) localised within neutrophils catalytically consumes
NO via the generation of radical intermediates and modulates NO
bioactivity via adversely impacting on vasomotor function [54].
Nitrite is a substrate for MPO and becomes oxidised to the reactive
oxidising and nitrating species nitrogen dioxide (NO2) which can
cause nitration of protein tyrosine residues [20]. Notably, the dif-
fuse immunoreactivity of MPO along the subendothelial space in
tissues from SCD patients reinforces ex vivo observations de-
scribing interactions between endothelial cells and MPO [21].
There is elevated MPO immunoreactivity throughout the alveolar
epithelium in lung tissues from patients with SCD, possibly con-
tributing to the pulmonary hypertension and acute chest syn-
drome prevalent in SCD [20].e (O2
•−) generated by uncoupled eNOS, xanthine oxidase, and NADPH oxidase reacts
aemoglobin, released by intravascular haemolysis and myeloperoxidase (MPO). The
ound I (I), the two electron oxidised form of the enzyme. Compound I can either
sequential one electron steps, forming compound II. Tyrosine (Tyr) and ascorbate
nd I, forming tyrosyl (Tyr) and ascorbyl (Asc) radicals. The reaction of nitric (NO)
nsumption of NO.
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Adherence of circulating blood elements with endothelial cells,
coagulopathy, inﬂammatory responses by leucocytes, vasocon-
striction due to decreased NO, and cell sickling in the case of SCD,
are among a complex series of factors known to contribute to
endothelial dysfunction and vascular obstruction [15,45]. The
chronic activation and dysfunction of endothelial cells result in
vascular damage in all organs [194,62,73]. Impaired cardiovascular
function, pulmonary hypertension and renal failure are among the
most signiﬁcant consequences [100,159,188].
The initiation, progression and resolution of vaso-occlusion
create an oxidative milieu and features common with ischaemia/
reperfusion (I/R) injury [14]. Tissue damage in reperfusion injury
can occur via xanthine oxidoreductase (XOR) which is an im-
portant source of oxygen free radical production [151]. During
experimental hypoxia, XOR to xanthine oxidase (XO) conversion
has been shown to be signiﬁcantly greater in the liver and kidneys
of SCD mice expressing a mixture of human HbS and murine Hb
[144]. Extensive hepatocellular injury accompanied by increased
plasma ALT levels, decreased liver XO immunoreactivity and cat-
alytic activity was observed in knockout-transgenic SCD mice even
under normoxic conditions [16]. Xanthine oxidase is elevated in
SCD patient plasma and in the arterioles and venules of SCD mice
[16,83]. Pro-inﬂammatory cytokines such as TNFα, IL-Iβ, and IFNγ,
shown to be enhanced in SCD [199], have also been associated
with increased xanthine oxidase in several tissues [79,98]. It has
been shown that elevated levels of circulating and vessel wall XO
in SCD lead to haemodynamic instability and contribute to the
pathogenesis of extensive vascular dysfunction [16]. Interestingly,
the interruption of blood ﬂow results in tissue ischaemia and thus
triggers the conversion of ATP to hypoxanthine and xanthine. After
blood ﬂow is restored hypoxanthine and xanthine oxidases, which
are released from hepatic and other tissues, catalyse the reaction
between oxygen and hypoxanthine and xanthine, respectively,
generating uric acid, NADPH and O (Fig. 2) [112,144,187].
Animal models of cardiac liver and kidney I/R all show in-
creased expression of inducible NOS (iNOS or NOS2) and elevated
tissue nitrite (NO2) and nitrate (NO3) levels (Fig. 2). NOS2 in-
hibitors signiﬁcantly improve organ function in tissue I/R injury
[102,107]. Increased NO production during I/R injury is cytotoxic
via direct reactions of NO with ROS, generating secondary species
capable of oxidation and nitration reactions. Enhanced im-
munoreactivity and selective nitration of liver and kidney actin is
detected in both SCD mice and humans [17].
I/R appears to increase the expression of NADPH oxidase in
PMNs, monocytes and endothelial cells (Fig. 2) [163,89]. Vascular
endothelial cells contain all the phox proteins and the small mo-
lecular weight GTP binding protein of the multicomponent pha-
gocytic NADPH oxidase system [26]. Endothelial cell NADPH oxi-
dase is therefore an important source of O2
•− and has been shown
to mediate microvascular dysfunction in SCD transgenic mice
[206]. NADPH oxidase inactivation was shown to be as effective as
SOD overexpression in abolishing both the leucocyte and platelet
adhesion responses that are normally observed in SCD mice [206].
5.7. Iron overload in β-thalassaemia
Iron overload is well documented in β-thalassaemia. It is caused
by the increased intra- and extra-cellular oxidative denaturation of
Hb and subsequent iron release, the recurrent blood transfusions,
especially in β-thalassaemia major, and the enhanced absorption
from the gastrointestinal (GI) tract [170]. The latter is attributed to
the decreased hepsidin levels observed in β-thalassaemia.
Hepsidin is produced in the liver and binds to the iron exporter
ferroprotein on the enterocytes, macrophages and liver cells,mediating its internalisation and subsequent degradation pre-
venting iron export from these cells [135,150]. Hepsidin is regu-
lated by the iron status, inﬂammation, hypoxia and erythropoietic
iron demand [138,155]. Its levels are decreased in β-thalasseamia
due to the ineffective erythropoiesis and subsequent enhanced
erythropoietic activity, which increases iron demand [139,3].
Oxidative stress has been implicated in both ineffective ery-
thropoiesis [53] and erythroid expansion [103].
Recent ﬁndings support the role of an erythroid regulator on
the reduction of hepsidin expression [148,198]. The erythroid
regulator is possibly a factor that is secreted from proliferating or
apoptotic precursors. TWSG1 (twisted gastrulation 1), isolated
from immature precursors in β-thalassaemia mice, and GDF15
(growth differentiation factor 15), found in the plasma of patients
with β-thalassaemia or other diseases characterised by ineffective
erythropoiesis, are two of the factors considered to play a role in
down-regulation of hepsidin expression [162,189,190]. Interest-
ingly, another member of the TGF-β superfamily, GDF11, has re-
cently been found to be associated with ineffective erythropoiesis
in β-thalassaemia by inducing oxidative stress [53].
Iron overload in SCD appears at a later stage and has a lower
occurrence [197]. This may be due to the lower ineffective ery-
thropoiesis and bone marrow erythroid expansion, which result in
reduced hepsidin suppression. As previously mentioned, increased
erythroid hyperplasia in SCD in mainly seen in the spleen [85],
moreover the fragmentation of erythroid precursors mostly occurs
during their medullary migration to the periphery [31]. In addi-
tion, hepsidin levels may also be affected by the enhanced in-
ﬂammation which increases hepsidin expression [156].
At high levels iron is an extremely toxic molecule. It can exit
circulating RBCs and migrate from the plasma to haematopoietic
and endothelial cells as well as various organs where it can pro-
mote oxidative reactions [57]. Myocardiopathy, liver cirrhosis, and
endocrine complications are among the long term consequences
of iron overload. Excess iron absorpted from the GI travels to the
liver through the portal vein and thus liver ﬁbrosis occurs as iron
promotes collagen synthesis. Transfusional iron on the other hand
ﬁrst accumulates in the reticuloendothelial system and is then
transferred to parenchymatous organs such as the heart and en-
docrine organs. The iron binding capacity of transferrin is over-
whelmed by the continuous accumulation of iron and this result in
the production of non-transferrin bound iron (NTBI) which is
highly toxic. Interestingly, the transport of NTBI to organs is faster
than that of transferrin bound iron leading to increased iron de-
position and subsequent oxidative organ damage [75]. Moreover,
the myocardium and endocrine tissues, unlike other tissues, have
L-type voltage dependant calcium channels that transport NTBI
and this possibly justiﬁes the pattern of transfusional iron de-
position in certain organs [145].6. Conclusion: scd vs β-thalassaemia
SCD and β-thalassaemia are heritable haemoglobinopathies
resulting from mutations affecting the structure or the level of
expression of the β-globin chain. Although they share many si-
milarities, the clinical manifestations of SCD are attributed to
chronic haemolytic anaemia resulting in endothelial damage and
vascular occlusion, whilst in β-thalassaemia ineffective ery-
thropoiesis and subsequent iron overload are the main features of
the disease.
6.1. Intracellular events
Kean et al. [85] have shown that SCD and β-thalassaemia mice
are equally anaemic with excessive erythroid hyperplasia but for
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duced compared to β-thalassaemia and the production of RBCs
cannot sustain the excessive peripheral destruction. On the con-
trary, in β-thalassaemia mice there are more erythroid precursors
than necessary to compensate for the reduced peripheral cell
numbers. This indicates that if the erythroid progenitors were
differentiating and transferred to the circulation efﬁciently, β-
thalassaemia mice would have more than enough RBCs in the
periphery and no anaemia [85]. This led to the conclusion that the
increased haemolysis in SCD exceeds the enhanced erythropoietic
activity, whereas in β-thalassemia ineffective erythropoiesis re-
sults in extremely low output of mature RBCs compared to the
produced erythroid progenitors. Oxidative stress appears to be
involved in both haemolysis and ineffective erythropoiesis.
Although the exact mechanisms and the differences between
SCD and β-thalassaemia are not quite understood, increased Hb
autoxidation seems to be the root of all evil. Within RBCs, auto-
xidation of Hbs, exacerbated by the unstable Hbs present in both
diseases, generates ROS, which are responsible for oxidative da-
mage of membrane and cytoskeletal components. Haeme and iron
released by the oxidative denaturation of Hbs are strong oxidising
agents themselves and can add to the oxidative stress. A recent
study by George et al. [63] revealed that in addition to Hb auto-
xidation and Fenton reactions, NADPH oxidase can also contribute
to ROS generation inside SCD RBCs. NADPH oxidase can be regu-
lated by both intra- and extracellular signals. Interestingly, in-
ﬂammatory cytokines, activated by ROS, can up-regulate NADPH
oxidase, creating a vicious cycle of ROS and inﬂammation.
Oxidative damage can disrupt normal membrane organisation
leading to PS exposure, which is a sign of eryptosis and a signal for
cell removal by the macrophage system. Macrophages can also
phagocytose senescent RBCs, which are recognised by the binding
of anti-band-3 NAbs to band-3/hemichrome clusters. Signs of in-
creased senescence and eryptosis can be observed in both SCD and
β-thalassaemia. However, in cases of extensive oxidative injury
RBCs will become damaged to such an extent that they will be
haemolysed instead.
An important factor to consider is that β-thalassaemia pre-
cursors are mainly removed by macrophages in the bone marrow
and extramedullary sites, following PS exposure or anti-band-3-
Nabs binding, whereas SCD RBCs are mostly haemolysed in the
periphery. In the case of β-thalassaemia, erythroid precursors
cannot overcome oxidative stress in order to go through differ-
entiation, whereas in SCD the problem begins when the RBCs
reach the circulation. One factor that can explain these differences
is the fact that HbS polymerisation, and thus increased autoxida-
tion, takes place mainly in the microcirculation, where there is low
oxygen saturation. In addition, α-globin chains may be more un-
stable than HbS and tend to aggregate, precipitate and autoxidise
at an earlier stage. In fact, α-globin aggregates have been found in
the polychromatophilic erythroblast stage, where increased hae-
moglobinisation takes place.
6.2. Extracellular events
Increased haemolysis leads to the release of Hb in the circula-
tion, with subsequent oxidative denaturation and production of
ROS, free haeme and iron. These oxidising molecules can damage
plasma proteins and lipids and can also intercalate into plasma
membranes promoting oxidative damage to the endothelium,
haematopoietic cells and variousorgans. Vascular inﬂammation is
one of the main consequences of haemolysis. It is characterised by
increased production of pro-inﬂammatory cytokines and leucocyte
inﬂux, which can generate more ROS, creating a vicious cycle of
oxidative stress and inﬂammation. Adhesion of RBCs, leucocytes
and platelets to the endothelium is another sign of inﬂammationand can also lead to hypercoagulation. Coagulation and in-
ﬂammation are further exacerbated because the bioavailability of
NO, an intercellular messenger with vasodilating, anti-thrombotic
and anti-inﬂammatory properties, is reduced as a consequence of
haemolysis and neutrophil activation.
All of the above can lead to extensive endothelial damage and
are evident in both SCD and β-thalassaemia, as they both experi-
ence increased haemolysis of RBCs in the periphery [127,181].
However, in SCD greater levels of haemolysis compared to β-tha-
lassaemia cause more severe problems. In addition, regular
transfusions, which are common practice for β-thalassaemia major
patients, can ameliorate the above pathologies. The excessive
haemolysis together with the sickling of RBCs, they can lead to
vaso-occlusive crises, which is a unique characteristic of SCD.
Vasculopathy can also lead to pulmonary hypertension, stroke, leg
ulcers and priapism, which are characteristic complications of SCD
[127]. In addition, vaso-occlusion results in I/R injury via the in-
creased expression of several plasma and endothelial enzymes
(xanthine oxidase, NADPH oxidase and iNOS), which give rise to
more ROS. It is therefore apparent that the oxidative stress in RBCs
generates a feedback loop for more ROS production.
On the contrary, the pathogenesis of β-thalassaemia is mainly
attributed to ineffective erythropoiesis and regular blood trans-
fusions which result in iron overload. Oxidative stress has been
implicated in ineffective erythropoiesis and the iron overload
generated by this promotes additional oxidative damage to cells
and tissues.
6.3. Protective mechanisms
Cytoprotective mechanisms are in place within cells to mini-
mise damage to the maturing RBC from oxidative stress. These
include PRDX2 (an antioxidant enzyme and chaperome for Hb and
haeme), AHSP (a chaperone for α-globin), NRF2 (an antioxidant
transcription factor regulating the expression of stress-response
genes), FOXO3 (a transcription factor promoting antioxidant en-
zyme expression and inhibition of proliferation of erythroid pre-
cursors; important for terminal differentiation), HRI/eIF2α/ATF4
(inhibitor of protein translation and initiator of stress response
cascade; important for terminal maturation) and PQC pathways
(e.g. UPS, autophagy; important for the balance of α-globin levels).
In addition, several antioxidant enzymes (e.g. SOD, catalase) and
molecules (e.g. GSH, vitamin E and C) function within RBCs to
neutralise the different reactive oxygen species. These mechan-
isms play a role in reducing oxidative stress during normal ery-
thropoiesis but are deregulated or overwhelmed in disease.
Protective mechanisms are also functioning in the circulation.
Haptoglobin and haemopexin can scavenge free Hb and haeme
respectively and are subsequently endocytosed by macrophages.
However, in the case of increased haemolysis, haptoglobin and
haemopexin become rapidly overwhelmed. Upon entering the cell,
haeme drives the expression of HO-1, which is the rate limiting
enzyme for the degradation of haeme, and ferritin, which takes up
the released iron to prevent its oxidative reactions.
Oxidative stress negatively impacts biological function at many
levels in both SCD and β-thalassaemia and is responsible for the
pathogenesis of these diseases. Better understanding of the main
players and biological events will provide new avenues for the
better management of these diseases.
Abbreviations: EryP: erythroid progenitors, WBCs: white blood
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